| pubmed-article:19010864 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19010864 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:19010864 | lifeskim:mentions | umls-concept:C0069676 | lld:lifeskim |
| pubmed-article:19010864 | lifeskim:mentions | umls-concept:C0165519 | lld:lifeskim |
| pubmed-article:19010864 | lifeskim:mentions | umls-concept:C1947901 | lld:lifeskim |
| pubmed-article:19010864 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:19010864 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:19010864 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:19010864 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:19010864 | pubmed:dateCreated | 2008-11-17 | lld:pubmed |
| pubmed-article:19010864 | pubmed:abstractText | Prostate cancer remains the second most frequent cause of tumor-related deaths in the Western world. Additional markers for the identification of prostate cancer development and progression are needed. Osteopontin (OPN), which activates matrix metalloproteinases (MMP), is considered a prognostic biomarker in several cancers. "In silico" and experimental approaches were used to determine whether OPN-mediated MMP activation may be a signal of prostate cancer progression. | lld:pubmed |
| pubmed-article:19010864 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19010864 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010864 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19010864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010864 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010864 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19010864 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19010864 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:CanevariSilva... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:FiginiMariang... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:LibraMassimoM | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:StivalaFranca... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:MalaponteGraz... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:TravaliSalvat... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:CastellanoGia... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:MazzarinoMari... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:GangemiPietro... | lld:pubmed |
| pubmed-article:19010864 | pubmed:author | pubmed-author:MarcheseFranc... | lld:pubmed |
| pubmed-article:19010864 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19010864 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:19010864 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:19010864 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19010864 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19010864 | pubmed:pagination | 7470-80 | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:meshHeading | pubmed-meshheading:19010864... | lld:pubmed |
| pubmed-article:19010864 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:19010864 | pubmed:articleTitle | Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. | lld:pubmed |
| pubmed-article:19010864 | pubmed:affiliation | Unit of Molecular Therapies, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. | lld:pubmed |
| pubmed-article:19010864 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19010864 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:4318 | entrezgene:pubmed | pubmed-article:19010864 | lld:entrezgene |
| entrez-gene:6696 | entrezgene:pubmed | pubmed-article:19010864 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19010864 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19010864 | lld:entrezgene |
| lhgdn:association:10785 | lhgdn:found_in | pubmed-article:19010864 | lld:lhgdn |
| lhgdn:association:23584 | lhgdn:found_in | pubmed-article:19010864 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19010864 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19010864 | lld:pubmed |
